AMLX ANALYSIS
Mis à jour
Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The firm focuses on streamlined clinical development and drug discovery. It specializes in developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the neuroinflammation and nerve cell death that characterize these disorders. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Gross margin TTM -20,475.44%
Operating margin TTM -41,275.09%
Net Profit margin TTM -42,545.96%
Return on Investment TTM -78.45%
Period Ending: Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Dec 31, 2020
Total Revenue 0 0 0.28 0.35
Gross Profit
Operating Income -47.81 -28.32 -54.37 -8.59
Net Income -47.85 -28.34 -59.59 -8.59
Name Company PE Industry PE
P/E Ratio TTM -10.84 23.39
Price to Sales TTM 4,610.78 7
Price to Cash Flow MRQ - 51.31
Price to Free Cash Flow TTM -12.7 56.76
Price to Book MRQ 5.45 9.41
Price to Tangible Book MRQ 5.44 102.93
Return on Equity TTM -100.65% 35.69
Return on Equity 5YA -100.65% 28.09
Return on Assets TTM 0% 11.42
Return on Assets 5YA -146.9% 8.98
Return on Investment TTM-78.45% 16.7
Return on Investment 5YA-113.25% 13.93
MY SOURCE: INVESTING.COM
do u think this pump was done by early investors who were thick n thin to regain their losses n pull the plug on unisightful investors
or will a miracle drug be produced and change the tides all i know is its always going to be profit over humanity funny considering how profit is derived from humanity
My interest will begin at 16.70 and 15. 40 as to wether some miracle will happen or wether it will kaput
SENNA SEASON
Gross margin TTM -20,475.44%
Operating margin TTM -41,275.09%
Net Profit margin TTM -42,545.96%
Return on Investment TTM -78.45%
Period Ending: Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Dec 31, 2020
Total Revenue 0 0 0.28 0.35
Gross Profit
Operating Income -47.81 -28.32 -54.37 -8.59
Net Income -47.85 -28.34 -59.59 -8.59
Name Company PE Industry PE
P/E Ratio TTM -10.84 23.39
Price to Sales TTM 4,610.78 7
Price to Cash Flow MRQ - 51.31
Price to Free Cash Flow TTM -12.7 56.76
Price to Book MRQ 5.45 9.41
Price to Tangible Book MRQ 5.44 102.93
Return on Equity TTM -100.65% 35.69
Return on Equity 5YA -100.65% 28.09
Return on Assets TTM 0% 11.42
Return on Assets 5YA -146.9% 8.98
Return on Investment TTM-78.45% 16.7
Return on Investment 5YA-113.25% 13.93
MY SOURCE: INVESTING.COM
do u think this pump was done by early investors who were thick n thin to regain their losses n pull the plug on unisightful investors
or will a miracle drug be produced and change the tides all i know is its always going to be profit over humanity funny considering how profit is derived from humanity
My interest will begin at 16.70 and 15. 40 as to wether some miracle will happen or wether it will kaput
SENNA SEASON
Note
price reached my interest prices and went up 90% plus
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.